Dextran 40 in 0.9% Sodium Chloride FDA Alerts
The FDA Alerts below may be specifically about Dextran 40 in 0.9% Sodium Chloride or relate to a group or class of drugs which include Dextran 40 in 0.9% Sodium Chloride.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings.
Recent FDA Alerts for Dextran 40 in 0.9% Sodium Chloride
Expiration Date Extension for Dextran 40 (10% LMD in 0.9% Sodium Chloride Injection) Lot 07011JT through June 1, 2022
September 29, 2021 -- This is to provide you with important information regarding Dextran 40 (10% LMD in 0.9% Sodium Chloride Injection), which is indicated to enhance blood flow, particularly in the microcirculation, and is manufactured by Hospira Inc., a Pfizer company.
Based upon FDA’s evaluation of stability data, FDA has extended the expiration date on one lot of 10% LMD in 0.9% Sodium Chloride Injection (#07011JT) in 500 mL bags for 11 months beyond its expiry date, as follows:
#07011JT: from July 1, 2021, to June 1, 2022.
The FDA is not requiring or recommending that the lots identified above be relabeled with new expiration dates. If you have bags of lot #07011JT in your current inventory, labeled with an expiration date of July 1, 2021, you may continue to maintain the product in your inventory and keep it available for use until June 1, 2022.
Please use available inventory on a first-in, first-out basis through the new expiration dates as noted above.
Source: FDA
